Napredna pretraga

Pregled bibliografske jedinice broj: 162470

Immune response to influenza vaccine (A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Beijing/184/93+ B/Yamanashi/166/98-like) in the elderly


Draženović, Vladimir; Ilić, Ankica; Sim, Renata; Božikov, Jadranka; Mlinarić-Galinović, Gordana
Immune response to influenza vaccine (A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Beijing/184/93+ B/Yamanashi/166/98-like) in the elderly // Periodicum biologorum, 102 (2003), 2; 147-151 (međunarodna recenzija, članak, znanstveni)


Naslov
Immune response to influenza vaccine (A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Beijing/184/93+ B/Yamanashi/166/98-like) in the elderly

Autori
Draženović, Vladimir ; Ilić, Ankica ; Sim, Renata ; Božikov, Jadranka ; Mlinarić-Galinović, Gordana

Izvornik
Periodicum biologorum (0031-5362) 102 (2003), 2; 147-151

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Influenza virus; vaccine; Ederly.

Sažetak
Background and purpose: The purpose of this paper was to ascertain the immunologic response to the vaccine given the elderly. Haemagglutination&#61485; inhibition (HI) antibodies are protective antibodies. Immune response to the administered vaccine can be determined based on antibody titre dynamics between the first and second sera (withdrawn after a 3-4-week interval). Patients and methods: Following WHO recommendations for the 2000/01 season, the vaccine contained virus antigens A/H1N1/New-Caledonia/20/99-like, A/H3N2/Moscow/10/99-like, B/Beijing/184/93 + B/Yamanashi/166/98-like. One hundred-nine people aged 65< from the area of Županja, Croatia, were vaccinated on 9-13 November 2000. Paired serum samples were taken from all subjects for the HI test. Results: In our study the described vaccine displayed: (1) number of seroconversions or a significant increase in specific HI antibody titre >30% for viruses A/H1N1, A/H3N2 and B/Beijing-93+Yamanashi-98, this occurring in 32, 44 and 66 subjects, respectively (for B/Beijing-97 in 29 subjects i.e. <30%), (2) whereas in viruses A/H3N2 and B/Beijing-93+Yamanashi-98 there was a mean geometric increase >2.0, i.e. 2.4 and 3.3, this was <2.0 in viruses A/H1N1 and B/Beijing-97 ; (3) while for viruses A/H1N1, A/H3N2 and B/Beijing-93+Yamanashi-98 the proportion of subjects achieving an HI antibody titre greater than 40 was >60%, (i.e. 67, 99, respectively 98%), for the B/Beijing-97 virus this was 55%. Conclusion: While for viruses A/H3N2 and B/Beijing-93+Yamanashi-98 the above vaccine is fully compliant with the vaccine assessment criteria, it fulfils two criteria of the three for virus A/H1N1. Of major concern was a lower than average immune response (fourfold increase of the specific antibody titre in 29.4%, respectively 26.6% subjects) to the vaccine components that should have afforded protection against virus types A/H1N1/New-Caledonia/20/99-like and B/Beijing/343/97-like that dominated in the 2000/01 outbreak.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Projekt / tema
0005002

Ustanove
Hrvatski zavod za javno zdravstvo

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Uključenost u ostale bibliografske baze podataka:


  • Excerpta Medica
  • Index Medicus